SecBot SecBot
PRESS-RELEASE ·Filed Oct 5, 2026

NMTC

NeuroOne Medical Technologies Corporation
MIXED
Impact 5/10
Horizonweeks Processed21d 7h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The record $4.5M purchase order and $5.4M open order book provide unusual forward revenue visibility for a small-cap medtech. Monitor the December 10-K for full P&L details and cash position; the EPS miss is modest but the revenue beat and order momentum are the primary drivers.

DirectionMixed
Confidencemedium
Horizonweeks
Latest settled — T+5d ⚠ clustered
NMTC ▼ -3.59% at T+5d
NEUTRAL call -3.59% · α vs SPY -4.01% · entry $1.12 → $1.08
Next anchor: T+20d in 7d
Latest observation: T+14 +2.15% FF3 residual α
Entry = T+0 close
Oct 5, 2026
via day close
T+1d
+1.35%
call +1.35% · α +0.80%
$1.13
settled 20d ago
T+5d
-3.59%
call -3.59% · α -4.01%
$1.08
settled 14d ago
T+20d
Pending
in 7d
T+60d
Pending
in 2mo

Price Chart

Loading chart...

Executive Summary

NeuroOne reported preliminary Q4 FY2026 product revenue of $3.8M (+38.4% YoY) and full-year revenue of $10.5M (+15.6% YoY), at the top of guidance. EPS of -$0.23 missed consensus of -$0.22 by 6.2%, but the company secured a record $4.5M purchase order and ended with $5.4M in open purchase orders, providing forward visibility.

Key Financial Metrics

EPS
−$0.23
est −$0.22 · -4.5%
Revenue
$3.8M
est $2.8M · +35.7% · +38.4% YoY
Rating
in line
Guidance
$9.2M-$10.5M
maintained

Key Facts

  • Preliminary Q4 FY2026 product revenue of ~$3.8M, up 38.4% YoY from $2.7M
  • Full-year FY2026 product revenue of ~$10.5M, up 15.6% YoY, at top of $9.2M-$10.5M guidance range
  • EPS of -$0.23 missed consensus estimate of -$0.22 (6.2% miss)
  • Record $4.5M product purchase order secured in September 2026; $1.0M shipped in Q4, remaining $3.6M to ship in H1 FY2027
  • Open purchase orders of $5.4M as of September 30, 2026, up 24.2% YoY in product orders
  • Full audited financial results expected in December 2026 with 10-K filing

Financial Impact

Revenue of $10.5M for FY2026, at top of guidance; EPS miss of $0.01 vs consensus

revenueeps

Risk Factors

  • Preliminary results subject to audit adjustment in December 10-K
  • EPS miss of 6.2% vs consensus may pressure near-term sentiment
  • Small revenue base ($10.5M) amplifies impact of any single order delay

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3374644
10 reports for NMTC
Performance horizon
67% Hit rate @ T+1 4 of 6 directional calls Went positive at some point 4 of 6 best @ T+60▲ +50.00%Jun 12, 2026
Filters
Rows
Reports for NMTC — sortable, filterable
TypeNow
Oct 5, 2026
21d ago
8-K
BULLISH ★ 6/10
$1.12 $1.13▲ +1.35%▲ +0.80%$0.8039 (−27.90%)
Oct 5, 2026
21d ago
Press Release
MIXED ★ 5/10
$1.12 $1.13▲ +1.35%▲ +0.80%$0.8039 (−27.90%)
Aug 27, 2026
8w ago
8-K
BULLISH ★ 5/10
$1.98 $1.77▼ −10.61%▼ −10.38%$0.8039 (−59.40%)
Aug 13, 2026
10w ago
8-K
MIXED ★ 5/10
$1.83 $1.94▲ +6.01%▲ +6.21%$0.8039 (−56.07%)
Jun 12, 2026
19w ago
424B5 / 8-K
BEARISH ★ 6/10
$3.32 $3.25▲ +2.11%▲ +1.51%$0.8039 (+75.79%)
May 22, 2026
22w ago
8-K
BEARISH ★ 7/10
$3.87 $3.73▲ +3.62%▲ +3.63%$0.8039 (+79.23%)
May 12, 2026
23w ago
8-K
BULLISH ★ 6/10
$4.39 $4.51▲ +2.73%▲ +2.16%$0.8039 (−81.69%)
May 4, 2026
25w ago
8-K
BULLISH ★ 5/10
$4.49 $4.43▼ −1.34%▼ −2.13%$0.8039 (−82.10%)
Apr 30, 2026
25w ago
8-K
NEUTRAL ★ 3/10
$4.70 $4.35▼ −7.45%▼ −7.67%$0.8039 (−82.90%)
Feb 25, 2026
34w ago
8-K
NEUTRAL ★ 3/10
$4.15 $4.02▼ −3.04%▼ −2.59%$0.8039 (−80.61%)
Showing 10 of 10

US Market Status

Market Closed — Opens Tue (16h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 5, 2026